50mg semaglutide Oral 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial such as those who are obese or have weight Weight Loss of 15% with

Common Side Effects (Both Medications) Gastrointestinal Effects (Most Common): Nausea (Zepbound: 25-29%, Wegovy: 24-44%) Diarrhea (Zepbound: 19-21%, Wegovy: 7-30%) Vomiting (Zepbound: 12%, Wegovy: 24%) Constipation (Zepbound: 12-17%, Wegovy: 14-24%) Abdominal pain or discomfort Indigestion and acid reflux General Side Effects: Fatigue or tiredness (approximately 4% of patients) Headache (more common with Wegovy) Dizziness Hair loss (temporary in most cases) Injection Site Reactions: Redness, itching, or bruising at injection site Slightly more common with Zepbound Managing Common Side Effects The good news is that most side effects are: Mild to moderate in severity Most pronounced during the initial weeks of treatment Tend to decrease as your body adjusts to the medication Manageable with proper strategies Practical Tips to Minimize Side Effects: Start Low, Go Slow: Both medications use gradual dose escalation specifically to minimize side effects Dietary Modifications: Eat smaller, more frequent meals

Many patients find that they have less hunger and fewer cravings

Answer a few questions about your health and goals

Future study and future work in this area may clarify optimal combination approaches for patients with obesity and type 2 diabetes